Neurologie up2date, Table of Contents Neurologie up2date 2020; 3(04): 411-424DOI: 10.1055/a-1011-7010 Myopathien und Neuropathien Idiopathische Inflammatorische Myopathien: Klinisches Spektrum und Diagnostik Julia Wanschitz Recommend Article Abstract All articles of this category Idiopathische inflammatorische Myopathien (IIM) bzw. Myositiden sind seltene und heterogene, jedoch mit einer hohen Morbidität behaftete Erkrankungen, die eine rasche Diagnose und Therapie erfordern. Die Kernsymptome einer akuten/subakuten Muskelschwäche und Erhöhung der Creatinkinase können mit verschiedenen Begleitsymptomen einhergehen und müssen im akuten Stadium von einer Rhabdomyolyse abgegrenzt werden. Eine Antikörperdiagnostik trägt wesentlich zur Subklassifikation und Prognoseeinschätzung der Myositiden bei. Full Text References Literatur 1 Feldman BM, Rider LG, Reed AM. et al. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008; 371: 2201-2212 2 Mall S, Buchholz U, Tibussek D. et al. A large outbreak of influenza B-associated benign acute childhood myositis in Germany, 2007/2008. Pediatr Infect Dis J 2011; 30: e142-146 3 Beydon M, Chevalier K, Al Tabaa O. et al. Myositis as a manifestation of SARS-CoV-2. Ann Rheum Dis 2020; 4 Megremis S, Walker TDJ, He X. et al. Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis. Ann Rheum Dis 2020; 5 Miller FW, Lamb JA, Schmidt J. et al. Risk factors and disease mechanisms in myositis. Nat Rev Rheumatol 2018; 14: 255-268 6 Rothwell S, Chinoy H, Lamb JA. et al. Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Ann Rheum Dis 2019; 78: 996-1002 7 Benveniste O, Drouot L, Jouen F. et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 2011; 63: 1961-1971 8 Khoo T, Stokes MB, Teo K. et al. Cardiac involvement in idiopathic inflammatory myopathies detected by cardiac magnetic resonance imaging. Clin Rheumatol 2019; 38: 3471-3476 9 Selva-OʼCallaghan A, Pinal-Fernandez I, Trallero-Araguas E. et al. Classification and management of adult inflammatory myopathies. Lancet Neurol 2018; 17: 816-828 10 Cabral BMI, Edding SN, Portocarrero JP. et al. Rhabdomyolysis. Dis Mon 2020; 66: 101015 11 Betteridge Z, Tansley S, Shaddick G. et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun 2019; 101: 48-55 12 Dani L, Holmqvist M, Martinez MA. et al. Anti-transcriptional intermediary factor 1 gamma antibodies in cancer-associated myositis: a longitudinal study. Clin Exp Rheumatol 2020; 38: 67-73 13 Albayda J, Pinal-Fernandez I, Huang W. et al. Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients. Arthritis Care Res (Hoboken) 2017; 69: 1771-1776 14 Marco JL, Collins BF. Clinical manifestations and treatment of antisynthetase syndrome. Best Pract Res Clin Rheumatol 2020; 15 Mescam-Mancini L, Allenbach Y, Hervier B. et al. Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis. Brain 2015; 138: 2485-2492 16 Takada T, Ohashi K, Hayashi M. et al. Role of IL-15 in interstitial lung diseases in amyopathic dermatomyositis with anti-MDA-5 antibody. Respir Med 2018; 141: 7-13 17 Allenbach Y, Uzunhan Y, Toquet S. et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: Study of 121 cases. Neurology 2020; 18 Hill CL, Zhang Y, Sigurgeirsson B. et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001; 357: 96-100 19 Baig S, Paik JJ. Inflammatory muscle disease – An update. Best Pract Res Clin Rheumatol 2020; 34: 101484 20 Christopher-Stine L, Casciola-Rosen LA, Hong G. et al. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010; 62: 2757-2766 21 Watanabe Y, Uruha A, Suzuki S. et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry 2016; 87: 1038-1044 22 Allenbach Y, Keraen J, Bouvier AM. et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain 2016; 139: 2131-2135 23 Mohassel P, Mammen AL. Anti-HMGCR myopathy. J Neuromuscul Dis 2018; 5: 11-20 24 Griggs RC, Askanas V, DiMauro S. et al. Inclusion body myositis and myopathies. Ann Neurol 1995; 38: 705-713 25 Pinal-Fernandez I, Casal-Dominguez M, Carrino JA. et al. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann Rheum Dis 2017; 76: 681-687 26 Farrow M, Biglands J, Alfuraih AM. et al. Novel Muscle imaging in inflammatory rheumatic diseases-a focus on ultrasound shear wave elastography and quantitative MRI. Front Med (Lausanne) 2020; 7: 434 27 Leeuwenberg KE, van Alfen N, Christopher-Stine L. et al. Ultrasound can differentiate inclusion body myositis from disease mimics. Muscle Nerve 2020; 61: 783-788 28 Oddis CV, Aggarwal R. Treatment in myositis. Nat Rev Rheumatol 2018; 14: 279-289
